A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

TERMINATED

Status

143

Enrollment

INDUSTRY

Sponsor class

Stopped Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted in its stead the results of another study \[MK-0431-234\].

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Sitagliptin Phosphate/Metformin HCl (JANUMET®)

Sponsor

Merck Sharp & Dohme LLC